Breaking News
Sort by:
Top Post
Novalis Biotech Invests in Ultra Sensitive Genomics Technology by Rarity Bioscience
Rarity Bioscience announces a new strategic investment from Belgium-based Novalis Biotech. The investment is facilitated […]
Sandoz Biologics License Application for Proposed Biosimilar Denosumab Accepted by US FDA
Sandoz, a global leader in off-patent (generic and biosimilar) medicines, today announced that the US […]
Egret Therapeutics Receives FDA Clearance of IND Application for EGT 101 for Treatment of Delayed Cerebral Ischemia
Egret Therapeutics, a clinical-stage biotechnology company focused on developing transformative therapies for neurological conditions, has […]
Orexo Submits New Drug Application to FDA for OX124, a High-dose Rescue Medication for Opioid Overdose
Orexo AB announces the submission of a New Drug Application (NDA) to the US Food and […]
RefleXion Receives FDA Clearance for Biology-Guided Radiotherapy Treatment for Early and Late-stage Cancers
RefleXion Medical, a therapeutic oncology company, today announced the US Food and Drug Administration (FDA) […]
Jesduvroq Approved by US FDA for Anaemia of Chronic Kidney Disease in Adults on Dialysis
GSK today announced that the US Food and Drug Administration (FDA) has approved Jesduvroq (daprodustat), […]
Genoscience Pharma receives FDA Orphan Drug Designation for ezurpimtrostat to treat HepatoCellular Carcinoma (HCC)
Genoscience Pharma, a clinical-stage biotech company developing unique lysosomotropic drug candidates for the treatment of […]
Ellipses Pharma Announces FDA Approval of IND Application for EP0042 for Patients With Acute Myeloid Leukaemia
Ellipses Pharma, a global drug development company focused on accelerating the development of cancer medicines […]
Ionis receives FDA Fast Track designation for Olezarsen in patients with Familial Chylomicronemia Syndrome
Ionis Pharmaceuticals today announced that the United States Food and Drug Administration (FDA) has granted […]
Xeris Biopharma Announces FDA Grants Orphan-drug Exclusivity for Recorlev
Xeris Biopharma, a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing […]
Nanoscope Therapeutics Receives Fast Track Designation by the FDA for MCO-010 for the Treatment of Stargardt Disease
Nanoscope Therapeutics, a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced […]
- Halozyme Appoints Barbara Duncan to its Board of Directors Read more
- Dianosic Raises €4.7M to Bring Treatment for Chronic Rhinitis into Clinical Trial Read more
- Clexio and Genetika+ Announce Partnership Using Proprietary Antidepressant Screening Platform Read more
- Mihir Patel Joins Cambia Health Solutions as Chief Pharmacy Officer Read more
- Sandoz Biologics License Application for Proposed Biosimilar Denosumab Accepted by US FDA Read more